Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: DVS SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 33
States / cities: Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death, Cardiac Arrhythmias, Hematologic Malignancies
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Low-Risk, Early Stage Breast Cancer
Interventions: Cryoablation; Device
Lead sponsor: IceCure Medical Ltd.; Industry
Eligibility: 70 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: Glendale, California • Germantown, Tennessee

Conditions: Acute Decompensated Heart Failure
Interventions: Experimental: Placebo, Experimental: Metolazone; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Huntington Disease
Interventions: ACR16, Placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more

Conditions: Generalized Tonic Clonic Seizures
Interventions: Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more

Conditions: Hepatic Encephalopathy, Liver Failure, Hepatitis, Chronic, Liver Cirrhosis
Interventions: MARS, Standard Medical Therapy; Device · Drug
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 6
States / cities: Birmingham, Alabama • San Diego, California • Chicago, Illinois + 3 more

Conditions: Compliance, Patient
Interventions: Experimental Product; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 60 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections
Interventions: Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: Dupont Merck; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Manhassett, New York + 2 more

Conditions: Depression, Postpartum Depression
Interventions: Mothers and babies Internet course and PPD informational brochure; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Crohn's Disease, Complex Perianal Fistula
Interventions: Placebo, Darvadstrocel; Other · Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 22
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 17 more

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Malignant Neoplasm
Interventions: FitBit, Gait Assessment Test, MC5-A Scrambler Therapy, Quality-of-Life Assessment, Quantitative Sensory Testing, Questionnaire Administration; Device · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Warts, Verruca (Warts), Verruca Vulgaris
Interventions: 9-valent human papillomavirus vaccine, Sterile Saline; Biological · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Testosterone Deficiency
Interventions: Jatenzo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acute-graft-versus-host Disease
Interventions: Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: Endometrial Cancer, Recurrent Endometrial Cancer
Interventions: LY3023414; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Depression, Major Depressive Disorder, Major Depression
Interventions: Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions; Device · Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acne Vulgaris on the Face
Interventions: DispersinB Acne Cleanser; Device
Lead sponsor: Kane Biotech Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoarthritis, Pain
Interventions: Placebo Gel, OLT1177 Gel; Drug
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Birmingham, Alabama • Milford, Connecticut • DeLand, Florida + 10 more

Conditions: Brain Tumor
Interventions: Interstitial Laser Therapy; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
Interventions: AdV-tk + valacyclovir; Biological
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:; Drug · Radiation
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairfax, Virginia

Search by objective public record fields.

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

Use of a Medical Food in Adults Undergoing Surgery

A Study of Efavirenz in Combination With Stavudine and Didanosine

Effectiveness of a Web-based Prevention Program for Postpartum Depression

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

Neurosurgical Use of Interstitial Laser Therapy (ILT)

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer